melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling
Melior Discovery
home
Therapeutic Areas
Safety Assessment

theraTRACE

Melior Pharmaceuticals

melior melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling

Melior Discovery psychiatric

Novel Object Recognition Test and Cognition Impact
Novel object recognition (NOR) is a classic cognitive test used to determine the ability of a compound to increase or impair learning and memory. This model is based on the natural tendency of rodents to investigate a novel object instead of a familiar one. The choice to explore the novel object reflects the use of learning and recognition memory. Contrary to most classically-used learning and memory paradigms which require long periods of animal training, the object recognition task offers the ability to obtain rapid information on the cognitive impact of a new drug.

The data illustrate a memory impairment (A) induced with the muscarinic antagonist scopolamine and a memory enhancement (B) with D-serine, an amino acid shown to have cognitive enhancement potential. Data are mean ± SEM; ***p<0.001 compared to vehicle.

 

If you are interested in Novel Object Recognition Test, please contact models@meliordiscovery.com to start the conversation.